Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 86-100

  Singh, Jaspreet ^a   Olle, Brittany ^a   Suhail, Hamid ^a   Felicella, Michelle M ^b   Giri, Shailendra ^a  

^a HENRY FORD HOSPITAL   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Abcd1 KO mice; ABCD2; AMPK 1; metformin; mitochondria; X ALD

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMP ACTIVATED PROTEIN KINASE ALPHA 1; AMP ACTIVATED PROTEIN KINASE ALPHA 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MESSENGER RNA; METFORMIN; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID;

ABCD2 GENE; ADRENOLEUKODYSTROPHY; AMPK ALPHA 1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR PARAMETERS; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; FATTY ACID OXIDATION; FIBROBLAST; GENE; GENE EXPRESSION REGULATION; GENE LOSS; GENETIC ASSOCIATION; GLIA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LOW DRUG DOSE; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL OXYGEN CONSUMPTION RATE; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WHITE MATTER;

EID: 84976471120     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13562     Document Type: Article

References (76)

1. Asheuer M., Bieche I., Laurendeau I., Moser A., Hainque B., Vidaud M. and Aubourg P. (2005) Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum. Mol. Genet. 14, 1293–1303.
2. Berger J., Forss-Petter S. and Eichler F. S. (2014) Pathophysiology of X-linked adrenoleukodystrophy. Biochimie 98, 135–142.
3. Cao J., Meng S., Chang E., Beckwith-Fickas K., Xiong L., Cole R. N., Radovick S., Wondisford F. E. and He L. (2014) Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J. Biol. Chem. 289, 20435–20446.
4. Carroll K. C., Viollet B. and Suttles J. (2013) AMPKalpha1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling. J. Leukoc. Biol. 94, 1113–1121.
5. Cartier N., Hacein-Bey-Abina S., Bartholomae C. C. et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818–823.
6. Contreras M., Sengupta T. K., Sheikh F., Aubourg P. and Singh I. (1996) Topology of ATP-binding domain of adrenoleukodystrophy gene product in peroxisomes. Arch. Biochem. Biophys. 334, 369–379.
7. Cool B., Zinker B., Chiou W. et al. (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3, 403–416.
8. Foretz M., Guigas B., Bertrand L., Pollak M. and Viollet B. (2014) Metformin: from mechanisms of action to therapies. Cell Metab. 20, 953–966.
9. Forss-Petter S., Werner H., Berger J., Lassmann H., Molzer B., Schwab M. H., Bernheimer H., Zimmermann F. and Nave K. A. (1997) Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. J. Neurosci. Res. 50, 829–843.
10. Fourcade S., Savary S., Albet S. et al. (2001) Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2): promoter analysis and role of the peroxisome proliferator-activated receptor PPARalpha. Eur. J. Biochem. 268, 3490–3500.
11. Fourcade S., Ruiz M., Guilera C. et al. (2010) Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum. Mol. Genet. 19, 2005–2014.
12. Fourcade S., Ferrer I. and Pujol A. (2015) Oxidative stress, mitochondrial and proteostasis malfunction in adrenoleukodystrophy: A paradigm for axonal degeneration. Free Radic. Biol. Med. 88 (Pt A), 18–29.
13. Galic S., Fullerton M. D., Schertzer J. D. et al. (2011) Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Investig. 121, 4903–4915.
14. Giri S., Nath N., Smith B., Viollet B., Singh A. K. and Singh I. (2004) 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J. Neurosci. 24, 479–487.
15. Gondcaille C., Depreter M., Fourcade S. et al. (2005) Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J. Cell Biol. 169, 93–104.
16. Gondcaille C., Genin E. C., Lopez T. E. et al. (2014) LXR antagonists induce ABCD2 expression. Biochim. Biophys. Acta 1841, 259–266.
17. Gonzalez-Barroso M. M., Anedda A., Gallardo-Vara E., Redondo-Horcajo M., Rodriguez-Sanchez L. and Rial E. (2012) Fatty acids revert the inhibition of respiration caused by the antidiabetic drug metformin to facilitate their mitochondrial beta-oxidation. Biochim. Biophys. Acta 1817, 1768–1775.
18. Hauton D. (2011) Does long-term metformin treatment increase cardiac lipoprotein lipase? Metabolism 60, 32–42.
19. Hinzey A. H., Kline M. A., Kotha S. R., Sliman S. M., Butler E. S., Shelton A. B., Gurney T. R. and Parinandi N. L. (2012) Choice of cyclodextrin for cellular cholesterol depletion for vascular endothelial cell lipid raft studies: cell membrane alterations, cytoskeletal reorganization and cytotoxicity. Indian J. Biochem. Biophys. 49, 329–341.
20. Jang J., Kang H. C., Kim H. S. et al. (2011) Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. Ann. Neurol. 70, 402–409.
21. Kamijo K., Kamijo T., Ueno I., Osumi T. and Hashimoto T. (1992) Nucleotide sequence of the human 70 kDa peroxisomal membrane protein: a member of ATP-binding cassette transporters. Biochim. Biophys. Acta 1129, 323–327.
22. Kane D. A., Anderson E. J., Price J. W. 3rd, Woodlief T. L., Lin C. T., Bikman B. T., Cortright R. N. and Neufer P. D. (2010) Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese rats. Free Radic. Biol. Med. 49, 1082–1087.
23. Kemp S., Wei H. M., Lu J. F., Braiterman L. T., McGuinness M. C., Moser A. B., Watkins P. A. and Smith K. D. (1998) Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat. Med. 4, 1261–1268.
24. Khan M., Singh J., Gilg A. G., Uto T. and Singh I. (2010) Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy. J. Lipid Res. 51, 1685–1695.
25. Kobayashi T., Shinnoh N., Kondo A. and Yamada T. (1997) Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Biochem. Biophys. Res. Commun. 232, 631–636.
26. Kodavanti U. P., Thomas R., Ledbetter A. D. et al. (2011) Vascular and cardiac impairments in rats inhaling ozone and diesel exhaust particles. Environ. Health Perspect. 119, 312–318.
27. Kristensen J. M., Larsen S., Helge J. W., Dela F. and Wojtaszewski J. F. (2013) Two weeks of metformin treatment enhances mitochondrial respiration in skeletal muscle of AMPK kinase dead but not wild type mice. PLoS ONE 8, e53533.
28. Kukidome D., Nishikawa T., Sonoda K. et al. (2006) Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 55, 120–127.
29. Kung J. and Henry R. R. (2012) Thiazolidinedione safety. Expert Opin. Drug. Saf. 11, 565–579.
30. Labuzek K., Suchy D., Gabryel B., Bielecka A., Liber S. and Okopien B. (2010) Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol. Rep. 62, 956–965.
31. Larsen S., Rabol R., Hansen C. N., Madsbad S., Helge J. W. and Dela F. (2012) Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration. Diabetologia 55, 443–449.
32. Li Y. Y., Yu L. F., Zhang L. N. et al. (2013) Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice. Toxicol. Appl. Pharmacol. 273, 325–334.
33. Lu J. F., Lawler A. M., Watkins P. A., Powers J. M., Moser A. B., Moser H. W. and Smith K. D. (1997) A mouse model for X-linked adrenoleukodystrophy. Proc. Natl Acad. Sci. USA 94, 9366–9371.
34. Martin-Montalvo A., Mercken E. M., Mitchell S. J. et al. (2013) Metformin improves healthspan and lifespan in mice. Nat. Commun. 4, 2192.
35. Miller R. A. and Birnbaum M. J. (2010) An energetic tale of AMPK-independent effects of metformin. J. Clin. Investig. 120, 2267–2270.
36. Morato L., Galino J., Ruiz M. et al. (2013) Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. Brain 136, 2432–2443.
37. Morita M. and Imanaka T. (2012) Peroxisomal ABC transporters: structure, function and role in disease. Biochim. Biophys. Acta 1822, 1387–1396.
38. Moser H. W. (2006) Therapy of X-linked adrenoleukodystrophy. NeuroRx 3, 246–253.
39. Mounier R., Theret M., Arnold L. et al. (2013) AMPKalpha1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab. 18, 251–264.
40. Nath N., Giri S., Prasad R., Salem M. L., Singh A. K. and Singh I. (2005) 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J. Immunol. 175, 566–574.
41. Nath N., Khan M., Paintlia M. K., Singh I., Hoda M. N. and Giri S. (2009a) Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 182, 8005–8014.
42. Nath N., Khan M., Rattan R. et al. (2009b) Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. Biochem. Biophys. Res. Commun. 386, 16–20.
43. Netik A., Forss-Petter S., Holzinger A., Molzer B., Unterrainer G. and Berger J. (1999) Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Hum. Mol. Genet. 8, 907–913.
44. Ofman R., Dijkstra I. M., van Roermund C. W., Burger N., Turkenburg M., van Cruchten A., van Engen C. E., Wanders R. J. and Kemp S. (2010) The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. EMBO Mol. Med. 2, 90–97.
45. O'Neill L. A. and Hardie D. G. (2013) Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 493, 346–355.
46. O'Neill H. M., Maarbjerg S. J., Crane J. D. et al. (2011) AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc. Natl Acad. Sci. USA 108, 16092–16097.
47. O'Neill H. M., Holloway G. P. and Steinberg G. R. (2013) AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity. Mol. Cell. Endocrinol. 366, 135–151.
48. Owen M. R., Doran E. and Halestrap A. P. (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348(Pt 3), 607–614.
49. Paintlia A. S., Gilg A. G., Khan M., Singh A. K., Barbosa E. and Singh I. (2003) Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol. Dis. 14, 425–439.
50. Pang T., Zhang Z. S., Gu M. et al. (2008) Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J. Biol. Chem. 283, 16051–16060.
51. Park C. Y., Kim H. S., Jang J., Lee H., Lee J. S., Yoo J. E., Lee D. R. and Kim D. W. (2013) ABCD2 is a direct target of beta-catenin and TCF-4: implications for X-linked adrenoleukodystrophy therapy. PLoS ONE 8, e56242.
52. Pojoga L. H., Yao T. M., Opsasnick L. A., Garza A. E., Reslan O. M., Adler G. K., Williams G. H. and Khalil R. A. (2014) Dissociation of hyperglycemia from altered vascular contraction and relaxation mechanisms in caveolin-1 null mice. J. Pharmacol. Exp. Ther. 348, 260–270.
53. Prasad R., Giri S., Nath N., Singh I. and Singh A. K. (2006) 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction. J. Neurosci. Res. 84, 614–625.
54. Pujol A., Ferrer I., Camps C. et al. (2004) Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum. Mol. Genet. 13, 2997–3006.
55. Quentin T., Kitz J., Steinmetz M., Poppe A., Bar K. and Kratzner R. (2011) Different expression of the catalytic alpha subunits of the AMP activated protein kinase–an immunohistochemical study in human tissue. Histol. Histopathol. 26, 589–596.
56. Reznick R. M. and Shulman G. I. (2006) The role of AMP-activated protein kinase in mitochondrial biogenesis. J. Physiol. 574, 33–39.
57. Sanders M. J., Ali Z. S., Hegarty B. D., Heath R., Snowden M. A. and Carling D. (2007) Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem. 282, 32539–32548.
58. Schluter A., Espinosa L., Fourcade S. et al. (2012) Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy. Hum. Mol. Genet. 21, 1062–1077.
59. Shapiro E., Krivit W., Lockman L. et al. (2000) Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 356, 713–718.
60. Singh J. and Giri S. (2014) Loss of AMP-activated protein kinase in X-linked adrenoleukodystrophy patient-derived fibroblasts and lymphocytes. Biochem. Biophys. Res. Commun. 445, 126–131.
61. Singh I. and Pujol A. (2010) Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis. Brain Pathol. 20, 838–844.
62. Singh J., Khan M. and Singh I. (2009) Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy. J. Lipid Res. 50, 135–147.
63. Singh J., Khan M. and Singh I. (2011) HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes. J. Lipid Res. 52, 2056–2069.
64. Singh J., Khan M., Pujol A., Baarine M. and Singh I. (2013a) Histone deacetylase inhibitor upregulates peroxisomal fatty acid oxidation and inhibits apoptotic cell death in abcd1-deficient glial cells. PLoS ONE 8, e70712.
65. Singh J., Khan M. and Singh I. (2013b) Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes. Biochim. Biophys. Acta 1831, 747–758.
66. Singh J., Suhail H. and Giri S. (2015) Loss of AMP-activated protein kinase induces mitochondrial dysfunction and proinflammatory response in unstimulated Abcd1-knockout mice mixed glial cells. Mediators Inflamm. 2015, 176983.
67. Stapleton D., Mitchelhill K. I., Gao G. et al. (1996) Mammalian AMP-activated protein kinase subfamily. J. Biol. Chem. 271, 611–614.
68. Strack T. (2008) Metformin: a review. Drugs Today 44, 303–314.
69. Subramaniam N., Sherman M. H., Rao R., Wilson C., Coulter S., Atkins A. R., Evans R. M., Liddle C. and Downes M. (2012) Metformin-mediated Bambi expression in hepatic stellate cells induces prosurvival Wnt/beta-catenin signaling. Cancer Prev. Res. (Phila.) 5, 553–561.
70. Uto T., Contreras M. A., Gilg A. G. and Singh I. (2008) Oxidative imbalance in nonstimulated X-adrenoleukodystrophy-derived lymphoblasts. Dev. Neurosci. 30, 410–418.
71. Viollet B., Guigas B., Sanz Garcia N., Leclerc J., Foretz M. and Andreelli F. (2012) Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond.) 122, 253–270.
72. Wang L. and Di L. J. (2015) Wnt/beta-catenin mediates AICAR effect to increase GATA3 expression and inhibit adipogenesis. J. Biol. Chem. 290, 19458–19468.
73. Wang D., Green M. F., McDonnell E. and Hirschey M. D. (2013) Oxygen flux analysis to understand the biological function of sirtuins. Methods Mol. Biol. 1077, 241–258.
74. Williams T., Courchet J., Viollet B., Brenman J. E. and Polleux F. (2011) AMP-activated protein kinase (AMPK) activity is not required for neuronal development but regulates axogenesis during metabolic stress. Proc. Natl Acad. Sci. USA 108, 5849–5854.
75. Winder W. W., Holmes B. F., Rubink D. S., Jensen E. B., Chen M. and Holloszy J. O. (2000) Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J. Appl. Physiol. 88, 2219–2226.
76. Yap F., Craddock L. and Yang J. (2011) Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription. Int. J. Biol. Sci. 7, 645–650.